Our Syapse team is looking forward to attending #ISPOR2024 from May 5th to 9th! Connect with us at the conference to learn more about how our cohorts can support your research in over 50 different tumor types. Schedule a meeting with us today: https://lnkd.in/eHeQQxC3
Syapse’s Post
More Relevant Posts
-
Meet the SRG Rat – a cutting-edge highly immunodeficient model for #biomedical research. Its larger size allows enhanced procedures and tumor burden. Transform your research with this innovative research model. https://okt.to/esHf09
-
Missed the Vizgen & Labroots #Webinar on unlocking the secrets of #Glioblastoma with #SpatialMultiomic analysis? It's not too late! 🌟 You can still access all the insights shared by Prof. Heiland from FAU Erlangen-Nürnberg by watching the webinar on-demand. Dive into their groundbreaking work on therapy resistance and tumor microenvironment changes. 👉 Register to Watch On-Demand: https://hubs.ly/Q02t6r5W0 #Vizgen #MERSCOPE #GlioblastomaResearch #CancerResearch #OnDemandLearning
-
-
Precision meets innovation in tumor assessment!🧑⚕️Join Gerry Thompson in a groundbreaking on-demand webinar and explore the collaborative #digitalRANO tool's capabilities and transform your approach to tumor assessment. 🔬 https://bit.ly/3OnW6zR
-
Take your RNA-seq experiments to the next level with insights from Roche! Compare library preparation kits and optimize your tumor profiling workflow for maximum impact. Learn more >>> https://hubs.ly/Q02v0kxG0
Application Note: Molecular profiling by RNA-sequencing
-
📢Welcome to read the paper "A pan-#cancer analysis of high mobility group box 1 and its role in human #tumorigenesis" 👥By Lin Wang et al. 🔗Full text: https://lnkd.in/gTywKXBC
-
-
Day 3 at #PepTalk2024. Today's topic is about how our MHC Monomers & Tetramers can help in facilitate tumor research and development. Our products come in several formats and exhibit high stability. If you are having trouble finding our poster #B20, don't worry - just come by our booth #217 and we'll give you all the information you need. We are excited to connect with all of you and exchange ideas! #KACTUS #CHIPepTalk #Antibodies #AntibodyTherepeutics #ProteinEngineering #AntibodyDiscovery #AntibodyCharacterization
-
-
Tumor Conference Module | Functions Explained Simply https://lnkd.in/eUHhwHAH
Smatos - Tumor Conference Module | Functions Explained Simply
https://www.youtube.com/
-
Early is Good presented multi-omics detection platform at #acsfall2023. Check out the abstract here: https://lnkd.in/g3fV_7DC #multiomics #bladdercancer #bcdx Thakshila Liyanage Asel Liyanage
-
-
Hear it from the experts
Join us for this first episode of our new 'ESMO Deep Dive: #BreastCancer' series, on 'Loco-regional Therapy in Times of Individualised (& Increasingly Neoadjuvant) Treatment Concepts 2024'. Tailored for oncologists with a solid understanding of this tumour type, our advanced series brings together prominent figures in the field to discuss the latest and emerging therapies. ⏲️7 Feb at 18:30 CET. https://ow.ly/HGy150QqY2p Icro Meattini Maria João Cardoso
-
-
Yesterday at #ASCO24, Shasqi’s Founder & CEO, José M. Mejía Oneto presented data from our Phase 2a study in patients with soft tissue sarcoma. This trial represents the first successful dose escalation of doxorubicin beyond 4x in a clinical trial: using our CAPAC technology to activate chemotherapy at the tumor, we were able to dose 12x the standard dose of doxorubicin per cycle without any DLTs, and with mild and manageable myelosuppression. Thanks to our PIs: Nam Bui, Vineet Kwatra, Christopher W. Ryan, MD, Erlinda Maria Gordon MD and Sant Chawla and to the patients and their families for participating in this study. Read the full poster here👇 https://bit.ly/3VpEuHR
-
